Candriam Luxembourg S.C.A. lessened its holdings in Becton Dickinson and Co (NYSE:BDX) by 0.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 55,250 shares of the medical instruments supplier’s stock after selling 294 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Becton Dickinson and were worth $11,827,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also made changes to their positions in the business. Vanguard Group Inc. grew its stake in Becton Dickinson and by 8.5% in the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after purchasing an additional 1,353,780 shares during the period. State Street Corp grew its stake in Becton Dickinson and by 3.5% in the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after purchasing an additional 342,873 shares during the period. Northern Trust Corp grew its stake in Becton Dickinson and by 4.0% in the 2nd quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock valued at $549,028,000 after purchasing an additional 106,966 shares during the period. Fundsmith LLP grew its stake in Becton Dickinson and by 0.3% in the 2nd quarter. Fundsmith LLP now owns 2,302,590 shares of the medical instruments supplier’s stock valued at $449,258,000 after purchasing an additional 5,977 shares during the period. Finally, Mawer Investment Management Ltd. grew its stake in Becton Dickinson and by 1.4% in the 3rd quarter. Mawer Investment Management Ltd. now owns 1,799,828 shares of the medical instruments supplier’s stock valued at $352,599,000 after purchasing an additional 24,761 shares during the period. Hedge funds and other institutional investors own 75.56% of the company’s stock.
BDX has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price objective for the company in a research note on Wednesday, January 3rd. Deutsche Bank set a $260.00 price objective on Becton Dickinson and and gave the company a “buy” rating in a research note on Friday, December 29th. Argus upped their price objective on Becton Dickinson and to $235.00 and gave the company a “buy” rating in a research note on Thursday, December 14th. They noted that the move was a valuation call. Stifel Nicolaus restated a “buy” rating and issued a $245.00 price objective on shares of Becton Dickinson and in a research note on Friday, November 3rd. Finally, Bank of America restated a “buy” rating and issued a $260.00 price objective on shares of Becton Dickinson and in a research note on Friday, January 19th. Four analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $237.27.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, topping the consensus estimate of $2.41 by $0.07. The company had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.33 EPS. research analysts forecast that Becton Dickinson and Co will post 10.95 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be paid a dividend of $0.75 per share. The ex-dividend date is Thursday, March 8th. This represents a $3.00 annualized dividend and a dividend yield of 1.37%. Becton Dickinson and’s payout ratio is 229.01%.
In related news, Director Timothy M. Ring sold 269,661 shares of the stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the sale, the director now owns 295,753 shares of the company’s stock, valued at approximately $64,420,918.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.00% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Becton Dickinson and Co (BDX) Holdings Cut by Candriam Luxembourg S.C.A.” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://sportsperspectives.com/2018/02/13/becton-dickinson-and-co-bdx-holdings-cut-by-candriam-luxembourg-s-c-a.html.
Becton Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.